Reaction
T-Cell Lymphoma reporting signals
As of the last recalculation, T-Cell Lymphoma appears in 1,127 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is AXICABTAGENE CILOLEUCEL (PRR 47.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Axicabtagene Ciloleucel | 25 | 47.8 | 47.9 |
| Brentuximab Vedotin | 21 | 38.5 | 38.6 |
| Mercaptopurine | 20 | 21.7 | 21.7 |
| Alemtuzumab | 21 | 20.4 | 20.4 |
| Valganciclovir Hydrochloride Powder, | 10 | 15.3 | 15.3 |
| Etoposide | 56 | 14.8 | 14.8 |
| Bleomycin Sulfate | 8 | 14.4 | 14.4 |
| Doxorubicin | 58 | 12.6 | 12.6 |
| Cyclophosphamide Injection, Solution | 105 | 12.0 | 12.0 |
| Cyclophosphamide | 105 | 12.0 | 12.0 |
| Cyclophosphamide For Injection | 105 | 12.0 | 12.0 |
| Gemcitabine | 15 | 7.1 | 7.1 |
| Ixekizumab | 9 | 4.5 | 4.5 |
| Pegfilgrastim | 17 | 3.2 | 3.2 |
| Dupilumab | 68 | 2.7 | 2.7 |